Systemic Inflammation and Risk of Thromboembolism, Mortality, and Treatment Response in Patients With Cancer Receiving Immune Checkpoint Inhibitors
{{output}}
Background: Immune checkpoint inhibitors (ICI) are widely used in cancer therapy, but biomarkers for thromboembolic risk, treatment response, and survival remain limited. We evaluated the association of systemic inflammatory indi... ...
